Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor off-target effects on endothelial function biomarker crossover study
NL-OMON42153Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ticagrelor, clopidogrel and prasugrel in coronary arteriosclerosis (3 arms), sponsored by Erasmus MC. Primary endpoint: Reactive hyperemia index at steady state. Started Dec 2015; status: active, not recruiting.
02
Drugs
ticagrelorclopidogrelprasugrel
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON42153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42153.